Details of HTA project
Last updated: 1 February 2012 - Next update due: 8 February 2012
Research type: |
NICE Evidence Review Group Report (ERG) in support of NICE's Single Technology Appraisal process. |
Project title: |
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix |
Project documents and links |
Updates on the status of this appraisal can be found on the NICE website
A synopsis of this project is included in Supplement 1 to Volume 14 of the HTA journal series View a brief abstract of the synopsis |
About ERG reports |
Please note: Evidence Review Group (ERG) reports do not contain Commercial in Confidence data. However there may be examples of where such data has been blacked out by the Technical Team at NICE. ERG reports are a record of what was submitted to the relevant NICE Appraisal Committee and have not been peer-reviewed beyond the team's own internal quality assurance. Further details of this appraisal can be found through the 'Project documents and links' section above. |
Project ref: |
08/91/01 |
Cost: |
This project has been commissioned by the HTA programme on behalf of the National Institute for Health and Clinical Excellence on a call-off contract basis. |
Chief Investigator : |
Centre for Health Economics (CHE), University of York |
Start Date: |
February 2009 |
Publication of this ERG report |
This ERG report has been delivered to both the HTA programme and the NICE Appraisal Committee and is available through the link above. A synopsis of the ERG report has now been published in a supplement to the HTA journal series. See above for link to Supplements Page. |
Project Abstract: |
No abstract available for this project |
Project Protocol: |
Project protocol not available |
URL of this page: |
http://www.hta.ac.uk/1859 |
News feeds